Advent Gains High-Potential ART Business Through Bharat Buy
Deal Gives Exit To Other PE Groups
With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.
You may also be interested in...
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.